{"filing":{"accession_number":"0001213900-26-062184","cik":"0001553643","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"ea0292521-8k_relmada.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm"},"events":[{"id":8490,"run_id":7451,"accession_number":"0001213900-26-062184","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Shareholders approved four proposals at the May 27, 2026 Annual Meeting: election of directors Casamento and Traversa, ratification of CBIZ CPAs P.C. as independent auditors, approval of a 3,000,000 share increase to the 2021 Equity Incentive Plan, and approval of a charter amendment increasing authorized common shares from 150 million to 200 million. All proposals passed with clear majorities.","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2402,"accession_number":"0001213900-26-062184","item_number":"5.03","item_title":"Amendments to","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a Charter Amendment increasing authorized common shares from 150 million to 200 million, approved by stockholders at the May 27, 2026 Annual Meeting and filed May 28, 2026. While this is a structural change that could signal future dilution or capital-raising activity, it is primarily a routine corporate governance amendment rather than a specific material event (earnings, M\u0026A, executive change, impairment, etc.). The increase in authorized shares is material to investors assessing dilution risk, but the taxonomy lacks a dedicated category for capitalization changes absent an accompanying issuance or transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:43:07.444071+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2403,"accession_number":"0001213900-26-062184","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports the outcomes of four proposals voted on at the May 27, 2026 Annual Meeting: election of directors (Casamento and Traversa), ratification of CBIZ CPAs P.C. as independent auditors, approval of a 3,000,000 share increase to the 2021 Equity Incentive Plan, and approval of a charter amendment increasing authorized common shares from 150,000,000 to 200,000,000. All proposals passed with clear majorities. This is material as it documents shareholder approval of significant corporate governance and equity plan matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:43:07.444071+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2402,"accession_number":"0001213900-26-062184","item_number":"5.03","item_title":"Amendments to","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a Charter Amendment increasing authorized common shares from 150 million to 200 million, approved by stockholders at the May 27, 2026 Annual Meeting and filed May 28, 2026. While this is a structural change that could signal future dilution or capital-raising activity, it is primarily a routine corporate governance amendment rather than a specific material event (earnings, M\u0026A, executive change, impairment, etc.). The increase in authorized shares is material to investors assessing dilution risk, but the taxonomy lacks a dedicated category for capitalization changes absent an accompanying issuance or transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:43:07.444071+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-05-28"},{"id":2403,"accession_number":"0001213900-26-062184","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports the outcomes of four proposals voted on at the May 27, 2026 Annual Meeting: election of directors (Casamento and Traversa), ratification of CBIZ CPAs P.C. as independent auditors, approval of a 3,000,000 share increase to the 2021 Equity Incentive Plan, and approval of a charter amendment increasing authorized common shares from 150,000,000 to 200,000,000. All proposals passed with clear majorities. This is material as it documents shareholder approval of significant corporate governance and equity plan matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:43:07.444071+00:00","company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","filing_date":"2026-05-28"}]}